The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Systemic Juvenile Idiopathic Arthritis (Juvenile Still's Disease).

What was studied

This is a guideline on a type of arthritis in children. It covers systemic JIA, also called juvenile Still's disease. A team of 35 members from 14 countries wrote it. The team had child and adult joint doctors and patient voices. They read other guidelines and searched past studies on 10 questions. Members then voted on each draft statement to reach agreement.

What they found

The team set out core rules and a list of statements. Some statements deal with macrophage activation syndrome, or MAS. The guideline backs early use of IL-1 or IL-6 blocking drugs. It advises against steroid drugs alone for sJIA without MAS. It supports cutting steroid doses once the disease is no longer active. It backs a switch of drug class if biologic drugs fail. When biologics are not available, it lists other standard drugs as options. It advises against NSAIDs alone as the first treatment. Less weight is put on lung disease linked to sJIA.

What it means for patients

The guideline aims to help doctors avoid delays in sJIA treatment. The authors want to guide doctors where health resources are limited. They hope less delay will lead to better results overall. It stresses that doctors and patients decide together. It also stresses treatment aimed at clear set goals.

Why it is not certain yet

These are expert views reached by vote, not a new trial. The abstract does not give the strength of each statement. It does not say how good the studies they found were. Health systems differ across the Asia Pacific. Some drugs, like biologics, may not be available everywhere.

Source

The Asia-Pacific League of Associations for Rheumatology Consensus Recommendations on the Management of Systemic Juvenile Idiopathic Arthritis (Juvenile Still's Disease).

We restate facts from the source record in our own words. The original wording belongs to its publisher.